Ben R. Taft, PhD

Senior Director of Chemistry, Via Nova Therapeutics

Bio

Ben has been working as a medicinal chemist since 2011. After completing his postdoc, he joined Novartis, where he conducted discovery-phase research for oncology indications. While at Novartis, he transitioned to infectious disease drug discovery. He then joined Via Nova Therapeutics, a Novartis antiviral spinout founded by Don Ganem and Kelly Wong, when Novartis exited the infectious disease space.

Drug Discovery
We chat with Ben Taft, Sr. Director of Chemistry at Via Nova Therapeutics, about SAR studies and the possible frontiers for bioactivity data.
|Article